| Literature DB >> 23351429 |
Xuhong Chang1, Yu Zhang, Meng Tang, Bei Wang.
Abstract
The paper is aimed to investigate the toxicity of nano-TiO2 and its potential harmful impact on human health using meta-analysis of in vitro and short-time animal studies. Data were retrieved according to included and excluded criteria from 1994 to 2011. The combined toxic effects of nano-TiO2 were calculated by the different endpoints by cell and animal models. From analysis of the experimental studies, more than 50% showed positive statistical significance except the apoptosis group, and the cytotoxicity was in a dose-dependent but was not clear in size-dependent manner. Nano-TiO2 was detained in several important organs including the liver, spleen, kidney, and brain after entering the blood through different exposure routes, but the coefficient of the target organs was altered slightly from animal models. It is possible that nano-TiO2 can induce cell damage related to exposure size and dose. Further studies will be needed to demonstrate that nanoparticles have toxic effects on human body, especially in epidemiological studies.Entities:
Year: 2013 PMID: 23351429 PMCID: PMC3599498 DOI: 10.1186/1556-276X-8-51
Source DB: PubMed Journal: Nanoscale Res Lett ISSN: 1556-276X Impact factor: 4.703
Figure 1Article selection flow chart.
Description of evidence for health effects of nano-TiOfrom cells models
| [ | U937 | 100 | 24~48 | 0.005~4 mg/ml | Apoptotic and necrotic modifications |
| [ | A549 | 63 | 4~18 | 80 μg/ml | DNA damage |
| [ | A549/NCI-H1299 | 20 | 24 | 0.3~1,000 μg/ml | Aggregated |
| [ | CHO/293 T | 10~60 | 24 | 25~325 μg/ml | Genotoxicity |
| [ | BEAS-2B | 5 | 24 | 100 μg/ml | Increases cytokines IL-6 and IL-8 |
| [ | HDF/A549 | 3.2~10 | 48 | 0.3~3,000 μg/ml | Cytotoxicity and inflammation |
| [ | U973 | 20 | 12~24 | 0.625~20 μg/ml | Transcriptional change of TIMP-1 |
| [ | BGC-823 | 20 | 24~72 | 100~800 mg/L | Cytotoxicity and inhibited growth |
| [ | NIH3 T3/HFW | 15 | 24~72 | 0.0005~50 μg/ml | Cytotoxicity and ROS |
| [ | WIL2-NS | 8.2 | 6~48 | 26~130 μg/ml | Cause genotoxicity and cytotoxicity |
| [ | PC12 cells | 21 | 6~48 | 1~100 μg/ml | ROS and apoptosis |
| [ | lymphocytes | 25 | 1~48 | 20~100 μg/ml | Induced genotoxicity |
| [ | MC3T3-E1 | 5/32 | 24~72 | 5~500 μg/ml | Cytotoxicity and pro-inflammatory |
| [ | Hela cells | 80 × 10 | 12 | 0.1~1.6 mg/ml | Cytotoxicity and OS-mediated |
| [ | THP-1 cells | 10 to 40 | 24 | 0.1~1.6 mg/ml | Reactive oxygen |
| [ | HDMEC | 70 | 24~72 | 5~50 μg/ml | No cytotoxicity and inflammatory |
| [ | CHL | 21 | 24/72 | 0.025~1.00 mg/ml | Cytotoxicity |
| [ | HLF | 21/80 | 24/48 | 5~80 mg/L | Inhibit GJIC |
| [ | A549 | 5 to 10 | 6 | 25~200 μg/ml | DNA damage |
| [ | Red cells | 15 | 3 | 1.25~20.0 g/L | MDA generations and hemolytic |
| [ | A549 | 25 | 1~24 | 100 μg/ml | ROS and inhibit the growth |
| [ | BGC-823 | 20 | 24 | 0.1~0.4 mg/ml | Increased ROS levels |
| [ | HaCaT | 20 to 35 | 4 | 10~300 μg/ml | Damaged structure and inhibited growth |
| [ | A549 | 5 | 24~72 | 5~160 μg/ml | Induced ROS |
| [ | L929 | 20 to 100 | 24~72 | 50~200 μg/ml | No cell proliferation and apoptosis |
| [ | 293 T and CHO | 10 | 24 | 10~500 μg/ml | Induced cell apoptosis |
| [ | HaCaT | 4~60 | 24 | 10~200 mg/ml | Cytotoxicity and apoptosis |
BEAS, Human bronchial epithelial cells; CHL, Classical Hodgkin lymphoma; HDMEC, Human dermal microvascular endothelial cells; GJIC, Gap junctional intercellular communication; HDL, human diploid fibroblast; HLF, Human lactoferrin; OS, Oxidative stress; NS, Nervous system; ROS, Reactive oxygen species.
Description of evidence for health effects of nano-TiOfrom mice and rats models
| [ | Digestive tract | 25~155 | 5 g/kg | 2 weeks | Transported to other tissues and organs |
| [ | Respiratory tract | 21 | 42 mg/m3 | 8 to 18 days | Lung inflammation and neurobehavioral toxicity |
| [ | Respiratory tract | 10/100 | 500 μg/mouse | 30 days | Pathological lesions in the brain and neurotoxicity. |
| [ | Intraperitoneal | 5 | 5~150 mg/kg | 14 days | Liver toxicity, inflammation, and apoptosis |
| [ | Respiratory tract | 25 | 1.25 mg | 7 days | Lung toxicities and presence of aggregates or agglomerates |
| [ | Skin | 4/60 | 5% TiO2 | 60 days | Retained in the stratum corneum and the basal cells |
| [ | Intraperitoneal | 5 | 5~150 mg/kg | 14 days | Liver DNA cleavage and hepatocyte apoptosis |
| [ | Intraperitoneal | 100 | 324~2592 mg/kg | 7/14 days | The toxicity of the liver, kidney, lung, and spleen |
| [ | Intraperitoneal | 5 | 5~150 mg/kg | 14 days | Caused serious damage to the liver and kidney |
| [ | Respiratory tract | <10 | 5~500 μg | 24 h | Induce lung inflammation |
| [ | Respiratory tract | 34.8 | 550 μg/m3 | 4 h | Do not induce lung inflammation |
| [ | Digestive tract | 20 to 30 | 5 g/kg | 14 days | Liver and kidney toxicity |
| [ | Intraperitoneal | 30 | 200~500 mg/kg | 17 days | Liver, kidney, and male productive toxicity |
| [ | Intraperitoneal | 21 | 300 mg/kg | 18 h | Lung and liver damage |
| [ | Intraperitoneal | 30 | 300 mg/kg | 18 h/10 days | No histopathological change in the tissue |
| [ | Intraperitoneal | 20~40 | 4.876~120.7 mg/kg | 14 days | Liver damage |
| [ | Respiratory tract | 25 | 1~10 mg/kg | 10 days | Lung damage |
| [ | Intraperitoneal | 30 | 200~500 mg/kg | 17 days | Slight damages in the liver, kidney, and heart |
| [ | Digestive tract | 20 to 30 | 5 g/kg | 14 days | Liver and kidney toxicity |
| [ | Respiratory tract | 10 | 1,500 mg/m3 | 7~28 days | Increased in pulmonary inflammation |
| [ | Caudal vein | 20 to 100 | 0.1~0.8 mg/ml | 5 days | Induce DNA damage of the liver and kidney |
| [ | Digestive tract | 4 | 5 g/kg | 14 days | No change in coefficients of the organs |
| [ | Intraperitoneal | 6.9 | 5~150 mg/kg | 14 days | Induced kidney toxicity |
| [ | Respiratory tract | 15 | 1~10 mg/kg | 7~days | Lung injury, changed the enzyme activities |
| [ | Caudal vein | 5 | 0.24 μg/mouse | 1~48 h | Increase content of Ti in the liver, lung, and spleen |
| [ | Respiratory tract | 80 | - | 1 month | Distribution of Ti in the neural system |
| [ | Respiratory tract | 50 | 0.5~50 mg/kg | 7 days | Induced oxidative stress in the liver and kidney |
| [ | Respiratory tract | 20~30 | 3.5~17.5 mg/kg | 5 weeks | Lung damage, oxidative effects, inflammation |
| [ | Intraperitoneal | 62 | 1~15 mg/kg | 21 days | Nephrotoxicity and tubular damages |
| [ | Respiratory tract | 5 | 0.8~20 mg/kg | 7 days | Liver and lung damage |
| [ | Respiratory tract | 5~10 | 0.4~40 mg/kg | 7 days | Changed enzyme activities |
| [ | Respiratory tract | 25.1 | 2~50 mg/m3 | 5 days | Enzyme activities and induced lung toxicity |
| [ | Respiratory tract | 28.4 | 5 mg/kg | 1 weeks | Lung damage |
| [ | Respiratory tract | 5 | 0.8~20 mg/kg | 7 days | Aggregate in the lung and kidney |
| [ | Respiratory tract | 5, 21, 50 | 0.5~50 mg/kg | 7 days | Pulmonary toxicity |
| [ | Respiratory tract | 20 to 30 | 3.5~17.5 mg/kg | 5 weeks | Immune system toxicity |
Cytotoxicity and enzyme activities in different times and doses
| ≤0.005 | 0/2 | 1/10 | 3/5 | 1/3 | 5/20 | 20 | 2/1 | 0/4 | 2/5 | 29 |
| ≤0.05 | 3/2 | 10/10 | 9/4 | 4/5 | 26/21 | 55 | 3/0 | 4/1 | 7/1 | 88 |
| ≤0.5 | 7/1 | 15/7 | 10/2 | 5/2 | 37/12 | 76 | 3/0 | 5/0 | 8/0 | 100 |
| ≤5 | 1/1 | 5/1 | 3/1 | 3/0 | 12/3 | 80 | 1/0 | 2/0 | 3/0 | 100 |
| ≤50 | 1/0/ | 1/0 | 0/0 | 0/0 | 2/0 | 100 | 1/0 | 1/0 | 2/0 | 100 |
| Total | 12/6 | 32/28 | 25/12 | 13/10 | 82/56 | 59 | 10/1 | 12/5 | 22/6 | 79 |
| Percentageb | 67 | 53 | 68 | 57 | - | - | 91 | 71 | - | - |
aNumber of positive/negative studies.
bPercentage of positive studies.
Genotoxicity and apoptosis in the different times and doses
| ≤6r | 2/0 | 2/0 | 0/0 | 1/ | 2/ | 0/0 | 0/0 | 3/0 | 100 |
| ≤24 | 3/0 | 5/0 | 1/0 | 2/3 | 4/3 | 1/0 | 1/0 | 9/6 | 60 |
| ≤48 | 4/0 | 4/0 | 1/0 | 1/3 | 2/2 | 1/0 | 0/0 | 5/5 | 50 |
| Total | 7/0 | 11/0 | 2/0 | 4/6 | 8/5 | 2/0 | 1/0 | 17/11 | 61 |
| Percentageb | 100 | 100 | 100 | 40 | 62 | 100 | 100 | - | - |
aNumber of positive/negative studies.
bPercentage of positive studies.
Inflammation and cytotoxicity in 24 h for the different doses
| | | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ≤0.005 | 0/1 | 0/2 | 0/3 | 0 | 0/2 | 1/6 | 0/3 | 0/2 | 1/13 | /7 |
| ≤0.05 | 0/1 | 0/2 | 0/3 | 0 | 0/3 | 7/3 | 4/2 | 0/2 | 11/10 | 52 |
| ≤0.5 | 1/1 | 1/1 | 2/2 | 50 | 2/2/ | 5/2 | 5/2 | 0/2 | 12/8 | 60 |
| ≤5 | 0/0 | 1/1 | 1/1 | 50 | 0/0 | 3/1 | 1/1 | 1/0 | 5/2 | 71 |
| Total | 1/3 | 2/6 | 3/9 | - | 2/7 | 16/12 | 10/8 | 1/6 | 29/33 | 47 |
| Percentageb | 25 | 25 | 25 | - | 22 | 57 | 56 | 14 | - | - |
aNumber of positive/negative studies.
bPercentage of positive studies.
Contents of Ti and coefficients in the different organs
| Contents of Ti | ≤7 | 4/2 | 3/0 | 1/2 | 5/1 | 0/1 | 1/1 | 14/7 | 67 |
| ≤14 | 5/1 | 5/0 | 4/1 | 4/1 | 3/0 | 1/2 | 22/5 | 81 | |
| ≤28 | 0/2 | 0/0 | 0/0 | 2/1 | 1/0 | 0/0 | 3/3 | 50 | |
| Total | 9/5 | 8/0 | 5/3 | 11/3 | 4/1 | 2/3 | 35 | 15 | |
| Percentageb | 64 | 100 | 63 | 79 | 80 | 40 | 70 | - | |
| Coefficient | ≤7 | 0/1 | 0/0 | 0/1 | 4/0 | 0/0 | 0/0 | 4/2 | 67 |
| ≤14 | 9/13 | 2/10 | 4/10 | 4/6 | 3/7 | 1/9 | 23/55 | 29 | |
| ≤28 | 0/2 | 0/2 | 0/2 | 1/3 | 0/0 | 0/2 | 1/11 | 8 | |
| Total | 9/16 | 2/12 | 4/13 | 9/9 | 3/7 | 1/11 | 28/68 | - | |
| Percentageb | 36 | 14 | 24 | 50 | 30 | 8 | 29 | - |
aNumber of positive/negative studies.
bPercentage of positive studies.
Combined effects of nano-TiOon various organs
| Digestive tract | 3/0 | 0/1 | 3/0 | 0/1 | 1/0 | 0/1 | 7/3 | 70 |
| Respiratory tract | 4/0 | 1/1 | 2/1 | 12/3 | 1/1 | 0/2 | 20/8 | 71 |
| Intraperitoneal injection | 7/2 | 1/1 | 5/1 | 2/2 | 1/0 | 2/1 | 18/7 | 72 |
| Skin | 1/0 | 1/0 | 1/0 | 1/0 | 0/1 | 0/1 | 4/2 | 67 |
| Caudal vein | 1/0 | 0/0 | 2/0 | 0/0 | 0/0 | 0/0 | 3/0 | 100 |
| Totala | 16/2 | 3/3 | 13/2 | 15/6 | 3/2 | 2/5 | 52/20 | - |
| Percentageb | 89 | 50 | 87 | 71 | 60 | 29 | 72 | - |
aNumber of positive/negative studies.
bPercentage of positive studies.